Inuxair (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

The beclometasone component binds to glucocorticoid receptors in airway cells, suppressing inflammatory gene expression and reducing swelling, mucus, and immune cell infiltration. Formoterol activates β2‑adrenergic receptors on airway smooth muscle, increasing cyclic AMP and causing prolonged relaxation of the bronchi. Together they provide anti‑inflammatory and bronchodilatory effects in a single inhalation.

The specific dose and dosing schedule of Inuxair are determined by the prescribing clinician based on the severity of the patient’s asthma or COPD, age, and response to therapy. Typical regimens may involve one or two inhalations daily, but the exact number of puffs, strength, and timing must be individualized and written on the prescription.

Safety data for Inuxair in pregnancy and lactation are limited. The potential benefits of controlling severe asthma or COPD may outweigh theoretical risks, but the product should only be used during pregnancy or while breastfeeding if clearly indicated by a qualified healthcare provider. The prescriber should assess the risk‑benefit profile for each patient.

To place an order, submit an enquiry on the Inuxair product page at gnhindia.com, specifying the required quantity and providing your institutional or trade credentials. GNH India’s commercial team will verify eligibility, then respond with pricing, availability, shipping details—including any cold‑chain requirements if applicable—and assist with the necessary import documentation.

Compared with single‑component inhalers, Inuxair offers the convenience of delivering both an inhaled corticosteroid and a long‑acting β2‑agonist in one device, which can improve adherence. Relative to other combination products, its specific ratio of formoterol to beclometasone may provide a distinct balance of anti‑inflammatory and bronchodilator potency, but clinical choice depends on individual response, guideline recommendations, and physician preference.

Inuxair should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture, heat and direct sunlight. The inhaler should be kept upright and the mouthpiece cleaned regularly according to the manufacturer’s instructions. Do not expose the device to freezing conditions, and replace it after the recommended number of doses has been delivered.

Inuxair is delivered via a metered‑dose inhaler. The patient should exhale fully, place the mouthpiece between the lips, and press the canister to release a puff while inhaling slowly and deeply. After holding the breath for about 5–10 seconds, the patient should exhale gently. Proper technique, including rinsing the mouth after use, helps maximize drug delivery and reduce oral side effects.

The most serious adverse reactions associated with Inuxair include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, and cardiovascular events like tachycardia, arrhythmias, or hypertension, especially in patients with underlying heart disease. Patients should seek immediate medical attention if they experience sudden worsening of breathing, chest pain, rapid heartbeat, or signs of an allergic reaction.

Inuxair is contraindicated in patients with known hypersensitivity to either formoterol, beclometasone, or any excipients in the inhaler. It should also be avoided in individuals who have experienced a severe asthma attack or COPD exacerbation triggered by a β‑agonist, as well as in patients with untreated respiratory infections that could worsen with corticosteroid therapy. Clinicians must evaluate each patient’s medical history before prescribing.